INZYUnknownMicro-Cap

Inozyme Pharma, Inc. Insider Trading Activity

Every SEC Form 4 insider transaction reported for Inozyme Pharma, Inc. (INZY), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are INZY insiders buying or selling?

Inozyme Pharma, Inc. insiders reported 27 open-market buys ($104.1M) and 4 sells ($7.9M) across 31 Form 4 filings — a net buying position of $96.2M.

Source: SEC EDGAR Form 4

Key Statistics (as of Apr 3, 2025)

Total Form 4 filings
31
SEC EDGAR
Insider filers
19
Insider buys (27)
$104.1M
Insider sells (4)
$7.9M

Insider sentiment

Net buying

Net insider flow of $96.2M in net buying.

Recent INZY insider transactions

DateInsiderRoleTypeSharesPriceValue
Apr 3, 2025Douglas A TrecoCEO & ChairmanSale8.8K$0.89$7.8K
Apr 3, 2024Douglas A TrecoCEOSale7.5K$6.94$52.2K
Aug 4, 2023Pivotal bioVenture Partners Fund I, L.P.DirectorPurchase833.3K$4.80$4.0M
Aug 4, 2023Robert Lorne HopfnerDirectorPurchase833.3K$4.80$4.0M
May 15, 2023Robert Lorne HopfnerDirectorPurchase447.9K$6.36$2.8M
Mar 30, 2023Robert Lorne HopfnerDirectorPurchase344.6K$4.54$1.6M
Mar 29, 2023Robert Lorne HopfnerDirectorPurchase207.8K$4.05$841.1K
Dec 19, 2022Henric Bjorn BjarkeSVP, COOPurchase21.5K$1.39$29.9K
Apr 21, 2022Bakker Juliet Tammenoms10% OwnerPurchase1.4M$3.69$5.0M
Apr 20, 2022Pivotal bioVenture Partners Fund I, L.P.DirectorPurchase1.1M$3.69$3.9M
Apr 20, 2022Henric Bjorn BjarkeSVP, COOPurchase27.1K$3.69$100.0K
Apr 20, 2022Axel BolteChief Executive OfficerPurchase67.8K$3.69$250.0K
Apr 20, 2022Robert Lorne HopfnerDirectorPurchase1.1M$3.69$3.9M
Apr 20, 2022Sanjay SubramanianSVP, CFOPurchase27.1K$3.69$100.0K
Jun 25, 2021Axel BolteChief Executive OfficerSale66.8K$0.00$6.68
Feb 1, 2021Novo Holdings A/S10% OwnerSale375.0K$21.00$7.9M
Jul 29, 2020Novo Holdings A/S10% OwnerPurchase375.0K$16.00$6.0M
Jul 29, 2020Sanofi10% OwnerPurchase81.3K$16.00$1.3M
Jul 29, 2020Rock Springs Capital Management LP10% OwnerPurchase600.0K$16.00$9.6M
Jul 28, 2020RA CAPITAL MANAGEMENT, L.P.10% OwnerPurchase600.0K$16.00$9.6M
Jul 28, 2020Peter W. Sonsini10% OwnerPurchase250.0K$16.00$4.0M
Jul 28, 2020Scott D Sandell10% OwnerPurchase250.0K$16.00$4.0M
Jul 28, 2020Joshua Makower10% OwnerPurchase250.0K$16.00$4.0M
Jul 28, 2020Mohamad Makhzoumi10% OwnerPurchase250.0K$16.00$4.0M
Jul 28, 2020Anthony A. Florence Jr.10% OwnerPurchase250.0K$16.00$4.0M

Showing the 25 most recent of 31 Form 4 filings for Inozyme Pharma, Inc..

Most active INZY insiders

  • Robert Lorne Hopfner6 filings
  • Pivotal bioVenture Partners Fund I, L.P.3 filings
  • Axel Bolte2 filings
  • Douglas A Treco2 filings
  • Henric Bjorn Bjarke2 filings

Ask anything about INZY insider activity

Use Trabud's AI agent to query Inozyme Pharma, Inc.'s Form 4 history in plain English — "Show me INZY CEO purchases this year" or compare it against any other ticker.

Open the AI agent

INZY insider trading FAQ

Are Inozyme Pharma, Inc. insiders buying or selling?

Across 31 SEC Form 4 filings, Inozyme Pharma, Inc. (INZY) insiders reported 27 open-market purchases totaling $104.1M and 4 sales totaling $7.9M. That is a net buying position of $96.2M.

How many insiders trade INZY stock?

19 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Inozyme Pharma, Inc.. The most recent filing was accepted on Apr 3, 2025.

Where does Trabud get INZY insider trading data?

All INZY insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content